ACCF/AHA and ESC Guidelines for treating asymptomatic LVSD (recommendation; Level of Evidence).
| ||ACCF/AHA |
Guidelines 2009 
Guidelines 2005 
|ACE inhibitor||(I; A)||(I; A)|
|Angiotensin receptor blockers||Post-MI and intolerant of ACE I (I; B) |
No prior MI and intolerant of ACE I (IIa; C)
|Post-MI (I; A)|
|Beta blockers||Recent or remote MI (I; A) |
No prior MI (I; C)
|Post-MI (I; B)|
|Implantable cardioverter defibrillator||≥40 days post-MI and LVEF ≤30% on optimal medical therapy (IIa; B) |
Nonischemic cardiomyopathy and LVEF ≤30% on optimal medical therapy (IIb; C)
|ACCF/AHA: American College of Cardiology Foundation/American Heart Association; ESC: European Society of Cardiology; LVSD: left ventricular systolic dysfunction; ACE inhibitor: angiotensin converting enzyme inhibitor; MI: myocardial infarction; LVEF: left ventricular ejection fraction.|
Reprinted, with permission, from Atherton, 2012 .